JP2021523931A5 - - Google Patents

Info

Publication number
JP2021523931A5
JP2021523931A5 JP2021500503A JP2021500503A JP2021523931A5 JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5 JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
eudragit
formulation according
mc1r
Prior art date
Application number
JP2021500503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523931A (ja
JPWO2019183472A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023575 external-priority patent/WO2019183472A1/en
Publication of JP2021523931A publication Critical patent/JP2021523931A/ja
Publication of JP2021523931A5 publication Critical patent/JP2021523931A5/ja
Publication of JPWO2019183472A5 publication Critical patent/JPWO2019183472A5/ja
Pending legal-status Critical Current

Links

JP2021500503A 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法 Pending JP2021523931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
US62/647,000 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (3)

Publication Number Publication Date
JP2021523931A JP2021523931A (ja) 2021-09-09
JP2021523931A5 true JP2021523931A5 (https=) 2022-03-28
JPWO2019183472A5 JPWO2019183472A5 (https=) 2022-03-28

Family

ID=67988087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500503A Pending JP2021523931A (ja) 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法

Country Status (13)

Country Link
US (1) US20220088146A1 (https=)
EP (1) EP3768245A4 (https=)
JP (1) JP2021523931A (https=)
KR (1) KR102743821B1 (https=)
CN (1) CN112188888A (https=)
AU (2) AU2019239300A1 (https=)
BR (1) BR112020019128A2 (https=)
CA (1) CA3095036A1 (https=)
EA (1) EA202092275A1 (https=)
IL (1) IL277496B2 (https=)
MX (1) MX2020009900A (https=)
PH (1) PH12020551596A1 (https=)
WO (1) WO2019183472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220137043A (ko) * 2020-02-03 2022-10-11 팔라틴 테크놀로지스 인코포레이티드 디아민-연결 수용체-특이적 고리형 펩티드
JPWO2024143501A1 (https=) * 2022-12-28 2024-07-04

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101726893B1 (ko) * 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
WO2010144341A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
CA2833676C (en) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
PL2659881T3 (pl) * 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20150307754A1 (en) * 2014-04-28 2015-10-29 Celanese Acetate Llc Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Similar Documents

Publication Publication Date Title
ES2241603T3 (es) Formulacion oral para la administracion al ileon que comprende un compuesto inhibidor del transporte de acidos biliares presentes en el ileon.
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
JP3806740B2 (ja) 薬剤運搬組成物
ES2645930T3 (es) Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
CN1182844C (zh) 富马酸二烷基酯的用途
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
JP3725542B2 (ja) ピコサルフェート剤形
AU2002226955B2 (en) Pharmaceutical dosage form with multiple coatings
JP2009523175A5 (https=)
MXPA04003367A (es) Formulacion oral microparticulada galenica para la liberacion retrasada y controlada de principios activos farmaceuticos.
JP3633936B2 (ja) センナ剤形
JP2022514569A (ja) 非晶質スパルセンタン組成物
ES2417330T3 (es) Minicomprimidos farmacéuticos para la liberación sostenida de acetato de flecainida
JP2021523931A5 (https=)
JP5778184B2 (ja) 上皮増殖因子の経口投与可能薬学的ペレット
WO2013169925A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2019513801A5 (https=)
CN105434398B (zh) 一种雷贝拉唑肠溶微丸及其制备方法
JPWO2019183472A5 (https=)
JP3282832B2 (ja) 持続性錠剤
KR20240125702A (ko) 중수소화 돔페리돈 조성물, 방법, 및 제조
WO2007010930A1 (ja) 口腔内崩壊製剤用の薬物含有被覆微粒子及びその製造方法
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法